On the afternoon of March 21, 2025, Dr. Chen Weijie, Chairman of Shanghai Lishan Biopharmaceutical Co., Ltd., and Dr. Zhu Chaoyu, General Manager of Keyin Wisdom (Shanghai) Pharmaceutical Co., Ltd., were invited to the Punan Branch of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine to hold a seminar on medical industry integration services, to deeply explore cooperation in scientific research, clinical practice, testing, and AI platforms. This conference, chaired by Fan Jincheng, Vice President of the Shanghai Modern Service Industry Federation, gathered representatives from multiple member units of the Big Health Service Committee, building an important bridge for the coordinated development of the big health industry.

At the beginning of the meeting, Lei Zhen, Secretary of the Party Committee of Punan Hospital, stated that as a national public secondary comprehensive hospital integrating medical treatment, teaching, scientific research, and preventive healthcare, Punan Hospital has achieved remarkable results in discipline construction, talent cultivation, and medical technology improvement. It actively responds to national policies and vigorously explores new models of medical industry integration. Subsequently, Vice President Ding Song introduced the hospital's efforts in the transformation of medical technology patents and expressed the hospital's high emphasis on scientific research and innovation. He hoped to work together with enterprises to find solutions and accelerate the pace of technological success from laboratories to clinical applications.

At this seminar, Dr. Chen Weijie, Chairman of Lishan Biotech, emphasized the company's four core business segments to the heads of various departments at Punan Hospital: (1) Among the five live biopharmaceutical (LBP) pipelines under development, the inflammatory bowel disease (IBD) pipeline has completed pharmacological efficacy research, the CMC engineering batch production has been approved by the FDA, and toxicology experiments are underway. IIT clinical trials will be conducted in the middle of this year; (2) The "Zhuowei No.1" IBD non-invasive early screening second-class medical device, based on Swarming bacteria as an IBD biomarker and a deep learning based image classifier, has become a new way to quickly and accurately identify IBD patients and healthy individuals with its foresight, safety, convenience, and high cost-effectiveness; (3) The iMAP platform, jointly built by Lishan Biotechnology and the Institute of Intelligent Medicine at Fudan University, provides precision medicine intelligent assistance for researchers in the field of microbiology, medical workers, drug developers, and big health practitioners; (4) The company's major health products include gut microbiota testing with precision medical prediction, probiotic series products based on exclusive patented formulas, gut microbiota transplantation (FMT) based on artificial intelligence precision matching, and exosome series products based on advanced immune technology, all of which comprehensively safeguard consumers' healthy lives.

After thorough discussions, Lishan Biotech and Punan Hospital have reached cooperation intentions in multiple fields, including medical device cooperation represented by the application of "IBD non-invasive detection chips in laboratory and digestive departments", scientific research cooperation represented by "molecular drug delivery assisted by gut microbiota" and "screening of kidney failure related microorganisms based on intelligent microbial application platforms", and clinical cooperation represented by "IIT clinical trials of related LBP pipelines in Punan Hospital".

Lishan Biotech has always adhered to the scientific belief of "reconstructing a healthy ecology with the power of microorganisms". The "five in one" cooperation between production, education, research, supply and marketing with Punan Hospital this time will solidly promote the clinical practice of Lishan live biopharmaceutical pipeline, and also empower Punan Hospital with a new precision medicine diagnosis and treatment system, bringing blessings to patients through the closed-loop of "detection intervention tracking".